Home Healthcare Pharmaceuticals Chronic Kidney Disease Drugs Market

Chronic Kidney Disease Drugs Market Size, Share & Trends Analysis Report By Drug Class (SGLT2 Inhibitors, ACE Inhibitor, Angiotensin II Receptor Blockers, Calcium Channel Blockers, Beta Blockers, Diuretics, Erythropoiesis-Stimulating Agents, Others), By Indication (Diabetic Kidney Disease, Hypertensive Nephropathy, Glomerulonephritis, Polycystic Kidney Disease, Chronic Tubulointerstitial Nephritis, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 17, 2026 | Author: Dhanashri B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Table Of Content

  1. Executive Summary
  2. Research Scope & Segmentation
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
  3. Market Opportunity Assessment
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
  4. Market Trends
    1. Drivers
    2. Market Warning Factors
    3. Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
  5. Market Assessment
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
  6. Chronic Kidney Disease Drugs Market Size Analysis
    1. Introduction
    2. Chronic Kidney Disease Drugs Market Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
      1. SGLT2 Inhibitors
      2. ACE Inhibitor
      3. Angiotensin II Receptor Blockers
      4. Calcium Channel Blockers
      5. Beta Blockers
      6. Diuretics
      7. Erythropoiesis-Stimulating Agents
      8. Others
    3. Chronic Kidney Disease Drugs Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Diabetic Kidney Disease
      2. Hypertensive Nephropathy
      3. Glomerulonephritis
      4. Polycystic Kidney Disease
      5. Chronic Tubulointerstitial Nephritis
      6. Others
    4. Chronic Kidney Disease Drugs Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
  7. North America Chronic Kidney Disease Drugs Market Size Analysis
    1. Introduction
    2. Chronic Kidney Disease Drugs Market Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
      1. SGLT2 Inhibitors
      2. ACE Inhibitor
      3. Angiotensin II Receptor Blockers
      4. Calcium Channel Blockers
      5. Beta Blockers
      6. Diuretics
      7. Erythropoiesis-Stimulating Agents
      8. Others
    3. Chronic Kidney Disease Drugs Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Diabetic Kidney Disease
      2. Hypertensive Nephropathy
      3. Glomerulonephritis
      4. Polycystic Kidney Disease
      5. Chronic Tubulointerstitial Nephritis
      6. Others
    4. Chronic Kidney Disease Drugs Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
    5. U.S.
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    6. Canada
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
  8. Europe Chronic Kidney Disease Drugs Market Size Analysis
    1. Introduction
    2. Chronic Kidney Disease Drugs Market Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
      1. SGLT2 Inhibitors
      2. ACE Inhibitor
      3. Angiotensin II Receptor Blockers
      4. Calcium Channel Blockers
      5. Beta Blockers
      6. Diuretics
      7. Erythropoiesis-Stimulating Agents
      8. Others
    3. Chronic Kidney Disease Drugs Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Diabetic Kidney Disease
      2. Hypertensive Nephropathy
      3. Glomerulonephritis
      4. Polycystic Kidney Disease
      5. Chronic Tubulointerstitial Nephritis
      6. Others
    4. Chronic Kidney Disease Drugs Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
    5. U.K.
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    6. Germany
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    7. France
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    8. Spain
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    9. Italy
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    10. Russia
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    11. Nordic
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    12. Benelux
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    13. Rest of Europe
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
  9. APAC Chronic Kidney Disease Drugs Market Size Analysis
    1. Introduction
    2. Chronic Kidney Disease Drugs Market Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
      1. SGLT2 Inhibitors
      2. ACE Inhibitor
      3. Angiotensin II Receptor Blockers
      4. Calcium Channel Blockers
      5. Beta Blockers
      6. Diuretics
      7. Erythropoiesis-Stimulating Agents
      8. Others
    3. Chronic Kidney Disease Drugs Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Diabetic Kidney Disease
      2. Hypertensive Nephropathy
      3. Glomerulonephritis
      4. Polycystic Kidney Disease
      5. Chronic Tubulointerstitial Nephritis
      6. Others
    4. Chronic Kidney Disease Drugs Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
    5. China
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    6. Korea
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    7. Japan
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    8. India
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    9. Australia
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    10. Taiwan
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    11. South East Asia
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    12. Rest of Asia-Pacific
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
  10. Middle East and Africa Chronic Kidney Disease Drugs Market Size Analysis
    1. Introduction
    2. Chronic Kidney Disease Drugs Market Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
      1. SGLT2 Inhibitors
      2. ACE Inhibitor
      3. Angiotensin II Receptor Blockers
      4. Calcium Channel Blockers
      5. Beta Blockers
      6. Diuretics
      7. Erythropoiesis-Stimulating Agents
      8. Others
    3. Chronic Kidney Disease Drugs Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Diabetic Kidney Disease
      2. Hypertensive Nephropathy
      3. Glomerulonephritis
      4. Polycystic Kidney Disease
      5. Chronic Tubulointerstitial Nephritis
      6. Others
    4. Chronic Kidney Disease Drugs Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
    5. UAE
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    6. Turkey
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    7. Saudi Arabia
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    8. South Africa
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    9. Egypt
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    10. Nigeria
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    11. Rest of MEA
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
  11. LATAM Chronic Kidney Disease Drugs Market Size Analysis
    1. Introduction
    2. Chronic Kidney Disease Drugs Market Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
      1. SGLT2 Inhibitors
      2. ACE Inhibitor
      3. Angiotensin II Receptor Blockers
      4. Calcium Channel Blockers
      5. Beta Blockers
      6. Diuretics
      7. Erythropoiesis-Stimulating Agents
      8. Others
    3. Chronic Kidney Disease Drugs Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Diabetic Kidney Disease
      2. Hypertensive Nephropathy
      3. Glomerulonephritis
      4. Polycystic Kidney Disease
      5. Chronic Tubulointerstitial Nephritis
      6. Others
    4. Chronic Kidney Disease Drugs Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
    5. Brazil
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    6. Mexico
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    7. Argentina
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    8. Chile
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    9. Colombia
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    10. Rest of LATAM
      1. Introduction
      2. Market Size & Forecast By Drug Class 2022-2034 (USD MILLION/ Units)
        1. SGLT2 Inhibitors
        2. ACE Inhibitor
        3. Angiotensin II Receptor Blockers
        4. Calcium Channel Blockers
        5. Beta Blockers
        6. Diuretics
        7. Erythropoiesis-Stimulating Agents
        8. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Diabetic Kidney Disease
        2. Hypertensive Nephropathy
        3. Glomerulonephritis
        4. Polycystic Kidney Disease
        5. Chronic Tubulointerstitial Nephritis
        6. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
  12. Competitive Landscape
    1. Chronic Kidney Disease Drugs Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    3. Tier Structure Analysis
    4. Recent Developments
  13. Market Players Assessment
    1. AstraZeneca (UK)
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Bayer AG (Germany)
    3. Otsuka Pharmaceuticals Co., Ltd.(Japan)
    4. Lilly (US)
    5. Novartis AG (Switzerland)
    6. Amgen Inc. (US)
    7. Hoffmann-La Roche Ltd. (Switzerland)
    8. Pfizer Inc. (US)
    9. AbbVie Inc. (US)
    10. GSK plc (UK)
    11. Takeda Pharmaceutical Company Limited (Japan)
    12. Johnson & Johnson (US)
    13. Zydus Lifesciences Limited (India)
    14. Sun Pharmaceutical Industries Ltd. (India)
    15. Kissei Pharmaceutical Co., Ltd. (Japan)
  14. Research Methodology
    1. Research Data
      1. Secondary Data
        1. Major Secondary Sources
        2. Key Data from Secondary Sources
      2. Primary Data
        1. Key Data from Primary Sources
        2. Breakdown of Primaries
      3. Secondary And Primary Research
        1. Key Industry Insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
  15. Appendix
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  16. Disclaimer
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.